NP39722f Lenalidomide
A Contract Award Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("THE AUTHORITY")
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £720K
- Sector
- HEALTH
- Published
- 21 Sep 2022
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014
1 buyer
- NHS National Services Scotland Edinburgh
13 suppliers
- Accord Devon
- Bristol Myers Squibb Pharmaceuticals London
- Glenmark Pharmaceuticals Europe Watford
- Morningside Pharmaceuticals Leicestershire
- Piramal CC West Drayton
- Ranbaxy London
- Sandoz Camberley
- Stragen Reigate
- Teva Castleford
- Thornton & Ross Huddersfield
- Wockhardt Wrexham
- Mylan Hatfield
- Zentiva Pharma London
Description
This Framework Agreement is for the supply of Lenalidomide to health boards across NHS Scotland. Full details are contained in section II.2 of this notice.
Total Quantity or Scope
The Supply of Lenalidomide capsules to NHS Scotland with the full range of presentation with Indications as the originator product. The Authority has awarded an unranked multi supplier framework on a line by line basis.
Award Detail
1 | Accord (Devon)
|
2 | Bristol Myers Squibb Pharmaceuticals (London)
|
3 | Glenmark Pharmaceuticals Europe (Watford)
|
4 | Morningside Pharmaceuticals (Leicestershire)
|
5 | Piramal CC (West Drayton)
|
6 | Ranbaxy (London)
|
7 | Sandoz (Camberley)
|
8 | Stragen (Reigate)
|
9 | Teva (Castleford)
|
10 | Thornton & Ross (Huddersfield)
|
11 | Wockhardt (Wrexham)
|
12 | Mylan (Hatfield)
|
13 | Zentiva Pharma (London)
|
Award Criteria
Pregnancy Prevention Programme | 15 |
price | 85 |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated value referred to in Section II.I.5 cover the initial twelve (12) months framework duration and the optional thirty-six (36) month extensions. (SC Ref:706739)
Reference
- ocds-h6vhtk-036a2e
- FTS 026426-2022